ES2157890T3 - Metodo para identificar compuestos que actuan como agonistas o antagonistas para proteinas implicadas en la transduccion de señales. - Google Patents

Metodo para identificar compuestos que actuan como agonistas o antagonistas para proteinas implicadas en la transduccion de señales.

Info

Publication number
ES2157890T3
ES2157890T3 ES91915183T ES91915183T ES2157890T3 ES 2157890 T3 ES2157890 T3 ES 2157890T3 ES 91915183 T ES91915183 T ES 91915183T ES 91915183 T ES91915183 T ES 91915183T ES 2157890 T3 ES2157890 T3 ES 2157890T3
Authority
ES
Spain
Prior art keywords
pigment
test cells
exogenous
disposition
gpc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91915183T
Other languages
English (en)
Inventor
Michael R Lerner
Ethan A Lerner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BRL Screening Inc
Original Assignee
Bunsen Rush Laboratories Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27070955&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2157890(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bunsen Rush Laboratories Inc filed Critical Bunsen Rush Laboratories Inc
Application granted granted Critical
Publication of ES2157890T3 publication Critical patent/ES2157890T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70571—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5041—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving analysis of members of signalling pathways
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G01N2333/726—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Neurology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)

Abstract

UN METODO PARA IDENTIFICAR UN COMPUESTO QUIMICO QUE ACTUA COMO AGONISTA PARA UN RECEPTOR DE SUPERFICIE DE CELULA ACOPLADA DE PROTEINA (GPC). EL METODO COMPRENDE: INTRODUCIR A CELULAS DE PRUEBA DE UNA LINEA CELULAR CAPAZ DE DISPERSAR O AGREGAR SU PIGMENTO EN RESPUESTA A UN ESTIMULO ESPECIFICO Y EXPRESAR UNA CODIFICACION DE CLONO EXOGENO PARA EL RECEPTOR DE GPC UN ESTIMULANTE QUE FIJA UN ESTADO INICIAL DE DISPOSICION DE PIGMENTO DONDE EL PIGMENTO SE AGREGA DENTRO DE LAS CELULAS DE PRUEBA SI LA ACTIVACION DE RECEPTOR GPC EXOGENO INDUCE LA DISPERSION DE PIGMENTO, O INTRODUCIR UN ESTIMULANTE QUE FIJA UN ESTADO INICIAL DE DISPERSION DE PIGMENTO DONDE EL PIGMENTO SE DISPERSA DENTRO DE LAS CELULAS DE PRUEBA SI LA ACTIVACION DE RECEPTOR GPC EXOGENO INDUCE LA AGREGACION DE PIGMENTO; CONTACTAR LAS CELULAS DE PRUEBA FIJADAS EN UN ESTADO INICIAL DE DISPOSICION DE PIGMENTO CON EL TEST QUIMICO; Y DETERMINAR SI LA DISPOSICION DE PIGMENTO EN LAS CELULAS DE PRUEBA TRATADAS CON EL PRODUCTO QUIMICO CAMBIA DE UN ESTADO INICIAL DE DISPOSICION DE PIGMENTO, DONDE UN CAMBIO EN LA DISPOSICION DE PIGMENTO OBSERVADA EN LAS CELULAS DE PRUEBA QUE EXPRESAN EL RECEPTOR GPC EXOGENO INDICA QUE EL PRODUCTO QUIMICO ES UN AGONISTA PARA EL RECEPTOR GPC EXOGENO.
ES91915183T 1990-07-19 1991-07-17 Metodo para identificar compuestos que actuan como agonistas o antagonistas para proteinas implicadas en la transduccion de señales. Expired - Lifetime ES2157890T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US55572490A 1990-07-19 1990-07-19
US07/732,476 US5462856A (en) 1990-07-19 1991-07-16 Methods for identifying chemicals that act as agonists or antagonists for receptors and other proteins involved in signal transduction via pathways that utilize G-proteins

Publications (1)

Publication Number Publication Date
ES2157890T3 true ES2157890T3 (es) 2001-09-01

Family

ID=27070955

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91915183T Expired - Lifetime ES2157890T3 (es) 1990-07-19 1991-07-17 Metodo para identificar compuestos que actuan como agonistas o antagonistas para proteinas implicadas en la transduccion de señales.

Country Status (9)

Country Link
US (2) US5462856A (es)
EP (1) EP0539518B1 (es)
JP (1) JP3270041B2 (es)
AT (1) ATE199980T1 (es)
CA (1) CA2087614C (es)
DE (1) DE69132564T2 (es)
DK (1) DK0539518T3 (es)
ES (1) ES2157890T3 (es)
WO (1) WO1992001810A1 (es)

Families Citing this family (106)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4138621A1 (de) * 1991-11-25 1993-06-17 Boehringer Ingelheim Int Verfahren zum screenen von substanzen mit modulierender wirkung auf einen rezeptorabhaengigen zellulaeren signaluebertragungsweg
WO1994002515A1 (en) * 1992-07-21 1994-02-03 Bunsen Rush Laboratories Inc. Oligomer library formats and methods relating thereto
US5707798A (en) * 1993-07-13 1998-01-13 Novo Nordisk A/S Identification of ligands by selective amplification of cells transfected with receptors
IT1261847B (it) * 1993-09-01 1996-06-03 San Romanello Centro Fond Metodo per marcare cellule eucariote.
FR2713645A1 (fr) * 1993-12-08 1995-06-16 Inst Nat Sante Rech Med Polypeptides à activité de récepteur aux mélanocortines, médicaments les comprenant, séquences codant pour eux, sondes, vecteurs et hôtes les exprimant et application au criblage de médicaments.
WO1996000739A1 (en) * 1994-06-29 1996-01-11 Merck & Co., Inc. Modified g-protein coupled receptors
AU4426296A (en) * 1994-08-11 1996-03-07 Takeda Chemical Industries Ltd. G protein coupled receptor protein, production, and use thereof
WO1996005221A1 (en) * 1994-08-16 1996-02-22 Human Genome Sciences, Inc. Calcitonin receptor
US6537764B1 (en) 1995-01-19 2003-03-25 Children's Medical Center Corporation Method of identifying inhibitors of C—C chemokine receptor 3
US6806061B1 (en) * 1995-01-19 2004-10-19 Children's Medical Center Corporation G protein-coupled receptor gene and methods of use therefor
US6090575A (en) * 1995-03-30 2000-07-18 Human Genome Sciences, Inc. Polynucleotides encoding human G-protein coupled receptor GPR1
US5998164A (en) * 1995-03-30 1999-12-07 Human Genome Sciences, Inc. Polynucleotides encoding human G-protein coupled receptor GPRZ
EP1145721A3 (en) * 1995-06-06 2003-12-03 Human Genome Sciences, Inc. Human G-protein chemokine receptor HDGNR10 (CCR5 receptor). Pharmaceutical composition
CA2221616A1 (en) * 1995-06-06 1996-12-12 Mark D. Adams Human g-protein receptor hibef51
WO1996039442A1 (en) * 1995-06-06 1996-12-12 Human Genome Sciences, Inc. G-protein receptor htnad29
US6025154A (en) 1995-06-06 2000-02-15 Human Genome Sciences, Inc. Polynucleotides encoding human G-protein chemokine receptor HDGNR10
CA2229287A1 (en) * 1995-08-14 1997-02-27 Cornell Research Foundation, Inc. Regulation of cellular functions by ectopic expression of non-endogenous cell signalling receptors
WO1997019352A1 (en) * 1995-11-22 1997-05-29 Novartis Ag Therapeutic agents and screening method
US7888466B2 (en) 1996-01-11 2011-02-15 Human Genome Sciences, Inc. Human G-protein chemokine receptor HSATU68
US6790656B1 (en) 1996-01-24 2004-09-14 Synaptic Pharmaceutical Corporation DNA encoding galanin GALR2 receptors
US5972624A (en) * 1996-01-24 1999-10-26 Synaptic Pharmaceutical Corporation Method of identifying ligands which bind recombinant galanin receptor (GALR2)
CN1165147A (zh) * 1996-02-07 1997-11-19 武田药品工业株式会社 鸟嘌呤核苷酸结合蛋白偶联受体蛋白质，其生产和应用
US6268214B1 (en) 1996-04-04 2001-07-31 Roche Diagnostics Gmbh Vectors encoding a modified low affinity nerve growth factor receptor
US6004808A (en) * 1996-06-21 1999-12-21 Aurora Biosciences Corporation Promiscuous G-protein compositions and their use
FR2751535B1 (fr) * 1996-07-25 1998-11-27 Oreal Utilisation de derives de la melatonine pour la la depigmentation de la peau et compositions les comprenant
US6329197B2 (en) 1996-10-09 2001-12-11 Synaptic Pharmaceutical Corporation DNA encoding galanin GALR3 receptors and uses thereof
US6087115A (en) * 1997-01-22 2000-07-11 Cornell Research Foundation, Inc. Methods of identifying negative antagonists for G protein coupled receptors
DE69837806T3 (de) 1997-01-28 2012-01-05 Human Genome Sciences, Inc. "death-domain"-enthaltender rezeptor 4 (dr4), ein mitglied der tnf-rezeptor superfamilie, welcher an trail (apo-2l) bindet
US6403305B1 (en) 1997-02-06 2002-06-11 Cornell Research Foundation, Inc. Methods of identifying peptide agonists or negative antagonists of a G protein coupled receptor
US5891720A (en) * 1997-04-17 1999-04-06 Millennium Pharmaceuticals, Inc. Isolated DNA encoding a novel human G-protein coupled receptor
US6342369B1 (en) 1997-05-15 2002-01-29 Genentech, Inc. Apo-2-receptor
US6528271B1 (en) * 1997-06-05 2003-03-04 Duke University Inhibition of βarrestin mediated effects prolongs and potentiates opioid receptor-mediated analgesia
US5891646A (en) * 1997-06-05 1999-04-06 Duke University Methods of assaying receptor activity and constructs useful in such methods
US7541151B2 (en) 1997-06-05 2009-06-02 Duke University Single-cell biosensor for the measurement of GPCR ligands in a test sample
CA2295991A1 (en) 1997-06-11 1998-12-17 Human Genome Sciences, Inc. Human tumor necrosis factor receptor tr9
US6183974B1 (en) 1997-07-31 2001-02-06 The General Hospital Corporation Screening assays for G protein coupled receptor agonists and antagonists
US5879665A (en) * 1997-09-25 1999-03-09 The Board Of Regents Of The University Of Oklahoma Composition for causing skin lightening
US6110448A (en) * 1997-09-25 2000-08-29 The Board Of Regents Of The University Of Oklahoma Method for causing skin lightening
US5919436A (en) * 1997-09-25 1999-07-06 The Board Of Regents Of The University Of Oklahoma Method of lightening skin
AU9796698A (en) * 1997-10-09 1999-05-03 Ixsys, Incorporated Method for identifying optimal binding ligands to a receptor
CA2327400A1 (en) * 1998-04-06 1999-10-14 Bunsen Rush Laboratories, Inc. Directed evolution biosensors
AU4028199A (en) * 1998-06-05 1999-12-30 Discovery Technologies Ltd. Transformed cell lines which express heterologous g-protein-coupled receptors
WO2000023594A1 (en) * 1998-10-22 2000-04-27 The General Hospital Corporation BIOACTIVE PEPTIDES AND PEPTIDE DERIVATIVES OF PARATHYROID HORMONE (PTH) AND PARATHYROID HORMONE-RELATED PEPTIDE (PTHrP)
USRE42190E1 (en) 1998-11-20 2011-03-01 Arena Pharmaceuticals, Inc. Method of identifying a compound for inhibiting or stimulating human G protein-coupled receptors
US7816492B2 (en) * 1998-11-20 2010-10-19 Arena Pharmaceuticals, Inc. Human G protein-coupled receptors
US20030017528A1 (en) * 1998-11-20 2003-01-23 Ruoping Chen Human orphan G protein-coupled receptors
AU4217299A (en) 1998-11-30 2000-06-19 General Hospital Corporation, The Pth1r and pth3r receptors, methods and uses thereof
DK1141237T3 (da) 1998-12-31 2006-02-13 Gen Hospital Corp PTH-receptor og screeningsassay der anvender denne
WO2000045179A2 (en) * 1999-01-27 2000-08-03 The Regents Of The University Of California Screening for modulators of g-protein subunit beta 3
US6929925B1 (en) 1999-01-27 2005-08-16 The Regents Of The University Of California Assays for sensory modulators using a sensory cell specific G-protein beta subunit
US6673554B1 (en) * 1999-06-14 2004-01-06 Trellie Bioinformatics, Inc. Protein localization assays for toxicity and antidotes thereto
AU7734800A (en) * 1999-09-29 2001-04-30 General Hospital Corporation, The Polypeptide derivatives of parathyroid hormone (pth)
US20050148018A1 (en) 1999-10-07 2005-07-07 David Weiner Methods of identifying inverse agonists of the serotonin 2A receptor
US7462457B2 (en) * 2000-08-30 2008-12-09 Johns Hopkins University School Of Medicine Identification of activated receptors and ion channels
US6913877B1 (en) 2000-09-11 2005-07-05 State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of Oregon State University Methods for detecting bioactive compounds
CA2424817A1 (en) 2000-10-06 2002-04-11 Quantum Dot Corporation Cells having a spectral signature, and methods of preparation and use thereof
US20050059031A1 (en) * 2000-10-06 2005-03-17 Quantum Dot Corporation Method for enhancing transport of semiconductor nanocrystals across biological membranes
US20020107193A1 (en) * 2000-11-09 2002-08-08 Glazner Gordon W. Therapeutic uses for IP3 receptor-mediated calcium channel modulators
US7175988B2 (en) 2001-02-09 2007-02-13 Human Genome Sciences, Inc. Human G-protein Chemokine Receptor (CCR5) HDGNR10
EP1366058B1 (en) 2001-02-09 2011-01-26 Human Genome Sciences, Inc. Human g-protein chemokine receptor (ccr5) hdgnr10
EP1385845B1 (en) 2001-05-05 2008-01-09 Smithkline Beecham Plc N-aroyl cyclic amines
AU2002339843B2 (en) * 2001-07-23 2007-12-06 The General Hospital Corporation Conformationally constrained parathyroid hormone (PTH) analogs
WO2003023366A2 (en) * 2001-09-12 2003-03-20 The State Of Oregon, Acting By And Through The State Board Of Higher Education On Behalf Of Oregon State University Method and system for classifying a scenario
US7393934B2 (en) 2001-12-21 2008-07-01 Human Genome Sciences, Inc. Human G-protein chemokine receptor (CCR5) HDGNR10
US20060009409A1 (en) 2002-02-01 2006-01-12 Woolf Tod M Double-stranded oligonucleotides
WO2003064621A2 (en) 2002-02-01 2003-08-07 Ambion, Inc. HIGH POTENCY siRNAS FOR REDUCING THE EXPRESSION OF TARGET GENES
EP1478656B1 (en) 2002-02-01 2009-09-16 Life Technologies Corporation Oligonucleotide compositions with enhanced efficiency
US20050079526A1 (en) * 2002-02-20 2005-04-14 Affinium Pharmaceuticals, Inc. Methods and apparatuses for characterizing refolding and aggregation of biological molecules
US20030182669A1 (en) * 2002-03-19 2003-09-25 Rockman Howard A. Phosphoinositide 3-kinase mediated inhibition of GPCRs
US7290215B2 (en) * 2002-06-03 2007-10-30 Microsoft Corporation Dynamic wizard interface system and method
US20040029275A1 (en) * 2002-08-10 2004-02-12 David Brown Methods and compositions for reducing target gene expression using cocktails of siRNAs or constructs expressing siRNAs
JP4334480B2 (ja) * 2003-03-19 2009-09-30 ザ ジェネラル ホスピタル コーポレイション α−ヘリックス安定化剤を用いる高次構造的に制約された副甲状腺ホルモン
DE602004031605D1 (de) * 2003-05-20 2011-04-14 Univ Glasgow Materialien und methoden die sich auf g-protein gekoppelte rezeptor oligomere beziehen
WO2005009358A2 (en) 2003-07-17 2005-02-03 The General Hospital Corporation Conformationally constrained parathyroid hormone (pth) analogs
EP1723178A4 (en) 2004-03-12 2007-12-12 Human Genome Sciences Inc HUMAN G-PROTEIN CHEMOKIN RECEPTOR (CCR5) HDGNR10
WO2005116653A2 (en) * 2004-04-13 2005-12-08 Arena Pharmaceuticals, Inc. Modulators of human g protein-coupled receptors for the treatment of hyperglycemia and related disorders
DOP2006000008A (es) 2005-01-10 2006-08-31 Arena Pharm Inc Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1
WO2007027225A2 (en) 2005-04-27 2007-03-08 Arena Pharmaceuticals, Inc. Combination therapy for the treatment of obesity and diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood glp-1 level
PE20071221A1 (es) 2006-04-11 2007-12-14 Arena Pharm Inc Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas
EP1971862B1 (en) * 2006-04-11 2010-11-10 Arena Pharmaceuticals, Inc. Methods of using gpr119 receptor to identify compounds useful for increasing bone mass in an individual
US8124360B2 (en) 2006-04-20 2012-02-28 Givaudan S.A. Use of a T1R2 nucleic acid sequence to identify tastants
WO2007121604A2 (en) 2006-04-20 2007-11-01 Givaudan Sa Method relating to sweetness enhancement
US20090165366A1 (en) * 2006-06-01 2009-07-02 Goran Nadezda Jovanovic Microreactor Process for Making Biodiesel
US8143374B2 (en) * 2006-08-04 2012-03-27 The General Hospital Corporation Polypeptide derivatives of parathyroid hormone (PTH)
US8039233B2 (en) * 2007-01-18 2011-10-18 Givaudan S.A. Nucleic acid sequences and their use in methods to identify umami modulatiors
EP2137322B1 (en) 2007-03-30 2013-02-27 Givaudan SA Methods to identify tas2r modulators
EP2187902B1 (en) * 2007-08-01 2013-04-17 The General Hospital Corporation Screening methods using g-protein coupled receptors and related compositions
EP2146210A1 (en) 2008-04-07 2010-01-20 Arena Pharmaceuticals, Inc. Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditions modulated by PYY
US8093255B2 (en) 2008-10-09 2012-01-10 Glaxo Group Limited Imidazo[1,2-A]pyrimidines as orexin receptor antagonists
US8129384B2 (en) 2008-10-09 2012-03-06 Glaxo Group Limited Imidazo[1,2-a]pyrazines as orexin receptor antagonists
GB0823467D0 (en) 2008-12-23 2009-01-28 Glaxo Group Ltd Novel Compounds
MX2011011127A (es) 2009-04-24 2011-11-18 Glaxo Group Ltd 3-azabiciclo[4.1.0] heptanos usados como antagonistas de orexina.
EP2470523A1 (en) 2009-08-24 2012-07-04 Glaxo Group Limited 5-methyl-piperidine derivatives as orexin receptor antagonists for the treatment of sleep disorder
US20120149711A1 (en) 2009-08-24 2012-06-14 Glaxo Group Limited Piperidine derivatives used as orexin antagonists
WO2011143406A2 (en) 2010-05-13 2011-11-17 The General Hospital Corporation Parathyroid hormone analogs and uses thereof
US10267796B2 (en) * 2010-10-25 2019-04-23 The Procter & Gamble Company Screening methods of modulating adrenergic receptor gene expressions implicated in melanogenesis
WO2012089606A1 (en) 2010-12-28 2012-07-05 Glaxo Group Limited Azabicyclo [4.1.0] hept - 4 - yl derivatives as human orexin receptor antagonists
WO2012089607A1 (en) 2010-12-28 2012-07-05 Glaxo Group Limited Novel compounds with a 3a-azabicyclo [4.1.0] heptane core acting on orexin receptors
US9671410B2 (en) 2011-01-16 2017-06-06 The Procter & Gamble Company Biomarker-based methods for identifying and formulating compositions that improve skin quality and reduce the visible signs of aging in skin
WO2013151982A1 (en) 2012-04-03 2013-10-10 Arena Pharmaceuticals, Inc. Methods and compounds useful in treating pruritus, and methods for identifying such compounds
US10966916B2 (en) 2014-11-10 2021-04-06 The Procter And Gamble Company Personal care compositions
EP3217948B1 (en) 2014-11-10 2020-09-16 The Procter and Gamble Company Personal care compositions with two benefit phases
US20160128927A1 (en) 2014-11-10 2016-05-12 The Procter & Gamble Company Personal Care Compositions With Two Benefit Phases
CN111225652A (zh) 2017-10-20 2020-06-02 宝洁公司 气溶胶泡沫洁肤剂
WO2019079409A1 (en) 2017-10-20 2019-04-25 The Procter & Gamble Company CLEANER FOR AEROSOL MOUSSE FOAM
EP3887824A1 (en) 2018-11-29 2021-10-06 The Procter & Gamble Company Methods for screening personal care products

Also Published As

Publication number Publication date
EP0539518B1 (en) 2001-03-21
CA2087614A1 (en) 1992-01-20
EP0539518A4 (es) 1994-02-02
US5462856A (en) 1995-10-31
CA2087614C (en) 2009-09-01
JP3270041B2 (ja) 2002-04-02
JPH06502757A (ja) 1994-03-31
DE69132564T2 (de) 2001-10-31
WO1992001810A1 (en) 1992-02-06
EP0539518A1 (en) 1993-05-05
DE69132564D1 (de) 2001-04-26
DK0539518T3 (da) 2001-11-12
ATE199980T1 (de) 2001-04-15
US6051386A (en) 2000-04-18

Similar Documents

Publication Publication Date Title
ES2157890T3 (es) Metodo para identificar compuestos que actuan como agonistas o antagonistas para proteinas implicadas en la transduccion de señales.
Keen et al. Transfer characteristics of the hair cell’s afferent synapse
D'Angelo et al. Theta-frequency bursting and resonance in cerebellar granule cells: experimental evidence and modeling of a slow k+-dependent mechanism
Galarraga et al. Cholinergic modulation of neostriatal output: a functional antagonism between different types of muscarinic receptors
Vaux et al. Social Support Resources, Behavior, and Appraisals: A Path Analysis.
WO1998010068A3 (en) Methods and reagents for discovering and using mammalian melanocortin receptor agonists and antagonists to modulate feeding behavior in animals
Stewart et al. Na+, K+ and Ca2+ currents in identified leech neurones in culture
Conti et al. The high variance of AMPA receptor-and NMDA receptor-mediated responses at single hippocampal synapses: evidence for multiquantal release
GB2347223B (en) Method of electrochemical analysis of an analyte
ES532280A0 (es) Un medio de ensayo para determinar la presencia de un ion en una muestra a ensayar
ATE83325T1 (de) Festphaseanalytische vorrichtung und verfahren zu ihrer verwendung.
DE3588124D1 (de) Vorrichtung, mit Verwendung in chemischen Prüfverfahren
ATE100203T1 (de) Testverfahren.
SE8008648L (sv) Bioanalysmetod
Moisescu et al. Sarcomere length effects on the Sr2+-and Ca2+-activation curves in skinned frog muscle fibres.
AU8749498A (en) Methods for identifying or screening agonists for and antagonists to ppar
Giacobassi et al. An integrative approach to the facile functional classification of dorsal root ganglion neuronal subclasses
Weetall et al. Heterologous desensitization of the high affinity receptor for IgE (Fc epsilon R1) on RBL cells.
Schuhmann et al. Essential role of the beta subunit in modulation of C‐class L‐type Ca2+ channels by intracellular pH
KR960702532A (ko) 인터루킨-5-수용체-의존성 세포 시그날 전달 경로에 대한 조절 효과를 갖는 물질을 스크리닝하는 방법(Process for screening substances having a modulating effect on an interleukine-5-receptor-dependent cellular signal transmission path)
WO1999055901A3 (en) Screening assay for identifying human purinoreceptor ligands
Damjanovich et al. Macromolecular dynamics and information transfer
Carlson et al. Release of octopamine from the photomotor neurones of the larval firefly lanterns
Schild pA, a new scale for the measurement of drug antagonism. 1947.
Zange et al. The Intracellular pH of a Molluscan Smooth Muscle During a Contraction–Catch-Relaxation Cycle Estimated by the Distribution of [14C] DMO and by 31P-NMR Spectroscopy

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 539518

Country of ref document: ES